Borneol in cardio-cerebrovascular diseases: Pharmacological actions, mechanisms, and therapeutics. (July 2021)

• Record Type: Journal Article
• Authors: Liu, Songyu; Long, Yu; Yu, Shuang; Zhang, Dingkun; Yang, Qiyue; Ci, Zhimin; Cui, Mingquan; Zhang, Yulu; Wan, Jinyan; Li, Dan; Shi, Ai; Li, Nan; Yang, Ming; Lin, Junzhi
• Is Part Of: Pharmacological research. Volume 169(2021)
• Publication Date: 2021-07
• Subjects: borneol (PubChem CID: 64685) -- (+)-borneol (PubChem CID: 6552009) -- (-)-borneol (PubChem CID: 1201518) -- (+)-isoborneol (PubChem CID: 6973640) -- (−)-isoborneol (PubChem CID: 6321405) -- isoborneol (PubChem CID: 6973640); CVDs cardio-cerebrovascular diseases -- BO borneol -- BBB blood-brain barrier -- ACEI ACE inhibitors -- DDIs drug-drug interactions -- TCM traditional Chinese medicine -- ANP Angong Niuhuang Pills -- DDP compound Danshen Dripping Pills -- NB natural borneol -- SB synthetic borneol -- GABA activating γ-aminobutyric acid -- TNF-α tumor necrosis factor-α -- IL-6 interleukin-6 -- AA arachidonic acid -- Aβ amyloid β-protein -- CIRI cerebral ischemia/reperfusion injury -- XNJ Xingnaojing Injection -- TTMP tetramethylpyrazine -- TDDS transdermal drug delivery system -- AUC area under the curve -- iNOS inducible nitric oxide synthase -- BMECs brain microvascular endothelial cells -- CG control group -- TJ tight junction -- P-gp P-glycoprotein -- Phy Physiological -- A1AR A1 Adenosine Receptor -- A2AAR A2A Adenosine Receptor -- eNOS endothelial nitric oxide synthase -- HUVEC human umbilical vein endothelial cell -- MTS mucociliary transport system -- XMT Xinmaitong tablets -- SSZT Shangshi Zhitong plasters -- BTB blood–tumor barrier -- ox-LDL low-density lipoprotein -- LOX-1 lipoprotein receptor-1 -- SJP Suxiao Jiuxin Pills -- SBP Shexiang Baoxin Pills -- ECG correct electrocardiogram -- MI myocardial ischemia -- ROS reactive oxygen species -- RNS reactive nitrogen free radicals -- CA catecholamine -- bc1–2/bax B-cell lymphoma 2/bcl2-Associated X -- AMI acute myocardial infarction -- Ca2+ calcium -- TRPV transient receptor potential vanilloid -- EDRF Endothelium-derived relaxing factor -- NOS NO synthase -- PGE1 prostaglandin E1 -- PGE2 prostaglandin E2 -- 5-HT 5-Hydroxytryptamine -- IS ischemic stroke -- CNS central nervous system -- MCAO middle cerebral artery occlusion -- ATP adenosine triphosphate -- GPx Glutathione peroxidase -- IL-s interleukin-s -- IL-1 interleukin-1 -- IL-sβ interleukin-sβ -- IL-1β interleukin-1β -- NF-κB the master immune transcription factor nuclear factor kappa B -- DBZ tanshinol borneol ester -- COX-2 cyclo-oxygenase-2 -- LOX-5 lipoxygenase-5 -- ICAM-1 intercellular adhesion molecule-1 -- MDR1a multidrug resistance 1a -- MDR1b multidrug resistance1b -- MRP1 multidrug resistance-associated protein 1 -- ZO-1 Zona Occludens 1 -- MUC5AC Mucin 5AC -- MUC5B Mucin 5B -- TG treatment group -- CM conventional medication -- MMP-2 matrix metallopeptidase-2 -- EEG electroencephalogram -- GXST Guanxin Shutong Capsule -- XNQ Xinnaoqing Soft Capsule; Borneol -- Cardio-cerebrovascular diseases -- Pharmacological actions -- Mechanisms -- Therapeutics; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2021.105627
• Languages: English
• ISSNs: 1043-6618

Abstract

Abstract: With the coming acceleration of global population aging, the incidence rate of cardio-cerebrovascular diseases (CVDs) is increasing. It has become the leading cause of human mortality. As a natural drug, borneol (BO) not only has anti-inflammatory, anti-oxidant, anti-apoptotic, anti-coagulant activities and improves energy metabolism but can also promote drugs to enter the target organs or tissues through various physiological barriers, such as the blood-brain barrier (BBB), mucous membrane, skin. Thus, it has a significant therapeutic effect on various CVDs, which has been confirmed in a large number of studies. However, the pharmacological actions and mechanisms of BO on CVDs have not been fully investigated. Hence, this review summarizes the pharmacological actions and possible mechanisms of BO, which provides novel ideas for the treatment of CVDs. Graphical Abstract: ga1